Research in Oncology最新文献_第4页

Simultaneous Bilateral Chest Wall Irradiation, Can Helical Tomotherapy Improve Dose Distribution? 同时双侧胸壁照射，螺旋断层治疗能改善剂量分布吗?

Research in Oncology Pub Date : 2018-11-07 DOI: 10.21608/RESONCOL.2018.5667.1066

A. Elashwah, A. Mousa, Ghadeer Nazer

{"title":"Simultaneous Bilateral Chest Wall Irradiation, Can Helical Tomotherapy Improve Dose Distribution?","authors":"A. Elashwah, A. Mousa, Ghadeer Nazer","doi":"10.21608/RESONCOL.2018.5667.1066","DOIUrl":"https://doi.org/10.21608/RESONCOL.2018.5667.1066","url":null,"abstract":"Background: Radiotherapy to bilateral breast cancer (BBC) is technically challenging because of the proximity to organs as the heart and lungs. Aim: We conducted this study tocompare helical tomotherapy (HT) to 3-dimensional conformal radiation therapy (3D-CRT) technique in bilateral chest wall irradiation regarding the coverage of target volume and the doses recorded at adjacent organs at risk. Methods: Ten patients with synchronous BBC who underwent bilateral mastectomy were included. Two plans were performed for each patient using HT and 3D-CRT. Results: Target volume included bilateral chest wall, bilateral supraclavicular and level III axillary lymph nodes. Prescription dose was 50 Gy/25 fractions in 5 weeks. The mean chest wall planning target volume (PTV) homogeneity index and conformality index were 0.15 and 1.09 in HT versus 0.37 and 1.43 in 3D-CRT plans (p= 0.012 and 0.031). At least 95% of the prescribed dose was covering 96% and 92% of the chest wall PTV for HT and 3D-CRT plans (p= 0.026). Helical tomotherapy plans achieved significant decrease in all cardiac parameters compared to 3D-CRT plans. Helical tomotherapy also achieved reduction in mean dose and V20 for both lungs in expense of higher low dose to normal healthy tissue and longer treatment time in comparison to 3D-CRT. Conclusion: For BBC patients treated with bilateral chest wall and supraclavicular lymph nodes irradiation, HT provides more conformal and homogenous plan than conventional 3D-CRT plans. Helical tomotherapy improves chest wall PTV coverage and decreases the dose to the heart and lungs in expense of more volume of normal tissues exposure to low doses of radiation and longer treatment time.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45170703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Value of C-reactive Protein and Erythrocyte Sedimentation Rate in Advanced Bladder Cancer c反应蛋白和红细胞沉降率在晚期膀胱癌中的临床价值

Research in Oncology Pub Date : 2018-10-21 DOI: 10.21608/RESONCOL.2018.4152.1060

M. Shehata, E. Elkhouly, H. Alagizy, S. Gohar, Radwa M. Shalaby

{"title":"Clinical Value of C-reactive Protein and Erythrocyte Sedimentation Rate in Advanced Bladder Cancer","authors":"M. Shehata, E. Elkhouly, H. Alagizy, S. Gohar, Radwa M. Shalaby","doi":"10.21608/RESONCOL.2018.4152.1060","DOIUrl":"https://doi.org/10.21608/RESONCOL.2018.4152.1060","url":null,"abstract":"Background: The identification of biomarkers would improve the management of advanced urinary bladder carcinoma. Aim: The current study assessed the potential prognostic role of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) in advanced stage bladder cancer. Methods: Forty-six patients with advanced urinary bladder carcinoma were included in the study. After consent, CRP and ESR were measured before treatment, after 2 cycles of chemotherapy and at the end of treatment. The relation between CRP and ESR serum measurements and patients' characteristics and treatment response were assessed. Results: Both CRP and ESR were elevated in all included patients with mean values ± standard deviation: 35.43 ± 12.65 and 57.17 ± 18.15, respectively. The baseline CRP level was higher in patients with metastatic disease. ESR was significantly elevated in association with squamous cell carcinoma pathology and hydronephrosis and in patients who died within one year of diagnosis (p = 0.003, 0.001 and 0.03; respectively). Patients who experienced disease progression after 2 cycles of platinum-based chemotherapy had higher levels of CRP and ESR. Serial measurements during the course of treatment revealed that both CRP and ESR levels declined significantly during treatment mainly among responding patients (p = 0.001). Conclusion: CRP and ESR might be useful noninvasive biomarkers in advanced urinary bladder carcinoma.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42373907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of MEK1 and DIAPH3 Expression in Colorectal Carcinoma MEK1和DIAPH3在大肠癌中的表达

Research in Oncology Pub Date : 2018-08-12 DOI: 10.21608/RESONCOL.2018.4042.1059

A. Foda, Mohamed A. Ahmed, H. Elkalla, Eman El-zahaf, H. Abdallah, H. Wagih, M. Sami

{"title":"Role of MEK1 and DIAPH3 Expression in Colorectal Carcinoma","authors":"A. Foda, Mohamed A. Ahmed, H. Elkalla, Eman El-zahaf, H. Abdallah, H. Wagih, M. Sami","doi":"10.21608/RESONCOL.2018.4042.1059","DOIUrl":"https://doi.org/10.21608/RESONCOL.2018.4042.1059","url":null,"abstract":"Background: Colorectal carcinoma (CRC) is one of the serious causes of morbidity and mortality worldwide. It is characterized by activating mutations in genes encoding Receptor Tyrosine Kinases (RAS, RAF, MEK1 or MEK2) which act as driving oncogenes. DIAPH3 deficiency has been reported to enhance cancer cell motility, invasion and metastasis and also correlates with aggressive behaviour of cancer. Aim: To study the overexpression of MEK1 and DIAPH3 in CRC patients and their prognostic significance. Methods: We examined the immunohistochemical expression of MEK1 and DIAPH3 using tissue microarray technique in 150 CRC specimens divided into two groups. The mucinous group (MG) included specimens of 56 mucinous adenocarcinoma and 19 signet ring cell carcinoma, while the non-mucinous group (NMG) included 75 non-mucinous adenocarcinoma specimens for comparison. Results: MEK1 and DIAPH3 were strongly expressed in >50% of the studied specimens. The positivity of MEK1 expression was significantly higher in NMG compared to MG (66.7% and 34.3%, respectively; p<0.001). In all cases, the overexpression of MEK1 was significantly associated with peri-tumoral and intra-tumoral lymphocytic response (p=0.005 and 0.008, respectively). Furthermore, MEK1 overexpression showed statistically significant correlation with better OS (p=0.023) in the whole group of patients. The expression of DIAPH-3 did not differ significantly between NMG and MG (53.3% and 47.1%, respectively; p=0.456). There was strong relation between the overexpression of MEK1 and DIAPH3 (p<0.001). Conclusion: The results suggest a potential synergistic role of MEK1 and DIAPH3 overexpression and the development of CRC. Further large scale studies are warranted.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44497661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Children Exposed to Treatments in Utero in Pregnant Patients with Breast Cancer: Experience from Two Large Egyptian Hospitals 儿童暴露于子宫内治疗的怀孕乳腺癌患者:从两家大型埃及医院的经验

Research in Oncology Pub Date : 2018-08-02 DOI: 10.21608/RESONCOL.2018.3244.1052

S. Talima, M. El-Daly, Mohammed Hammam, A. Bader

{"title":"Children Exposed to Treatments in Utero in Pregnant Patients with Breast Cancer: Experience from Two Large Egyptian Hospitals","authors":"S. Talima, M. El-Daly, Mohammed Hammam, A. Bader","doi":"10.21608/RESONCOL.2018.3244.1052","DOIUrl":"https://doi.org/10.21608/RESONCOL.2018.3244.1052","url":null,"abstract":"Background: Pregnancy-associated breast cancer (PABC) is one of the common malignancies during pregnancy. Limited data is present about the effect of anticancer therapy on children born to mothers exposed to in utero treatments. Aim: To describe the outcome of pregnancy in a cohort of Egyptian patients treated for PABC. Methods: We reviewed all breast cancer cases diagnosed during pregnancy at two large Egyptian institutions between January 2009 and December 2016. Thirty-eight patients with complete obstetric and fetal data were included. Results: All patients received anthracycline-based chemotherapy in the 2nd and 3rd trimesters and 9 of them received paclitaxel. The mean gestational age at delivery was 35.7 ± 3.4 weeks. The mean birth weight was 2736 ± 768 grams. Congenital anomaly (cleft lip and tongue tie) was reported in only one (4%) child. Perinatal death occurred in one (4%) baby due to prematurity. One (4%) child was exposed to trastuzumab in utero in the 1st trimester and he was completely healthy. Two (8%) other children were exposed to tamoxifen with no complications either neonatal or postnatal.Conclusion: Chemotherapy during pregnancy may be used with minimal maternal and fetal complications. Multidisciplinary approach is crucial for better management. Continued long-term follow-up of the children in this cohort is required.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41896595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Four versus Six Cycles of Pemetrexed/Platinum as a First Line Treatment of Malignant Pleural Mesothelima: Results of a Randomized Phase II Study 培美曲塞/铂作为恶性胸膜间皮瘤一线治疗的4 vs 6个周期:一项随机II期研究的结果

Research in Oncology Pub Date : 2018-07-12 DOI: 10.21608/resoncol.2018.4306.1062

A. Nagy, Hesham Elwakeel, O. Abdel-Rahman

{"title":"Four versus Six Cycles of Pemetrexed/Platinum as a First Line Treatment of Malignant Pleural Mesothelima: Results of a Randomized Phase II Study","authors":"A. Nagy, Hesham Elwakeel, O. Abdel-Rahman","doi":"10.21608/resoncol.2018.4306.1062","DOIUrl":"https://doi.org/10.21608/resoncol.2018.4306.1062","url":null,"abstract":"Background: Pemetrexed-platinum is the standard first line treatment of patients with malignant pleural mesothelioma (MPM). Optimal number of pemetrexed-platinum chemotherapy cycles is not yet known with certainty. Aim: To compare 4 cycles versus 6 cycles of pemetrexed-platinum regimen as a 1st line treatment in MPM. Methods: This was a randomized phase II study (1:1) which was conducted at a single institution. Arm A received 4 cycles of pemetrexed-platinum, while Arm B received 6 cycles. The 1ry outcome of the current study was overall survival. It was assessed through Kaplan-Meier survival estimates as well as a multivariate Cox regression model adjusted for other relevant baseline clinicopathological characteristics. Results: A total of 60 patients were included into the current study (30 in each arm). Kaplan-Meier survival analysis according to the number of cycles of chemotherapy did not reveal a significant survival difference between both subsets (p = 0.194). Multivariate Cox regression analysis for factors affecting overall survival did not show an overall survival difference based on treatment arm (p = 0.105). Conclusions: Six cycles does not appear to improve the overall survival of MPM patients compared to four cycles. Shorter course of treatment should be considered in resource-limited settings like Egypt.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44553859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Perioperative Algorithm as a Novel Method for Lymph Node Assessment in Stage I Endometrial Cancer 围手术期算法作为一期子宫内膜癌淋巴结评估的新方法

Research in Oncology Pub Date : 2018-07-08 DOI: 10.21608/RESONCOL.2018.3345.1053

Hayam E. S. Atta, H. Hegab, O. Elashkar, M. Meleis, D. Abdallah

{"title":"Perioperative Algorithm as a Novel Method for Lymph Node Assessment in Stage I Endometrial Cancer","authors":"Hayam E. S. Atta, H. Hegab, O. Elashkar, M. Meleis, D. Abdallah","doi":"10.21608/RESONCOL.2018.3345.1053","DOIUrl":"https://doi.org/10.21608/RESONCOL.2018.3345.1053","url":null,"abstract":"Background: The uterus has a complex lymphatic drainage consisting of many groups that are in danger of endometrial cancer (EC) spread. Lymph node metastasis is a genuine pointer of poor prognosis requiring adjuvant therapy. Lymphatic mapping surgically can be done by blue dye labeling and perioperative algorithm. Aim: To assess the role of perioperative sentinel lymph nodes (SLN) mapping algorithm in reducing the necessity of pelvic lymphadenectomy. Methods: Fifty patients with early stage I EC underwent surgical staging. Transcervical injection of methylene blue was used, laparotomy was done and retroperitoneal spaces were opened. All lymph nodes were histopathologically examined and the negative SLN were ultrastaged. Results: Methylene blue dye injection resulted in blue lymph nodes in 20 (40%) cases, suspicious in 2 (4%) and negative in 28 (56%). Histopathological examination of sampled lymph node showed metastases in 18/20 (90%) of blue nodes, 1/2 (50%) of suspicious nodes and 0/28 (0%) of negative nodes. There were no false negative cases in this study and the detection rate was 89%. Conclusion: Perioperative algorithm accuracy and simplicity make it a reliable approach for lymph node assessment in early stage EC.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47927746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of Exogenous Neurotropic Factor Administration on Occurrence and Severity of Paclitaxel-Induce Neuropathy in Breast Cancer Patients. An open label Pilot Study. 外源性神经营养因子对紫杉醇诱导的乳腺癌患者神经病变发生及严重程度的影响。一项开放标签试点研究。

Research in Oncology Pub Date : 2018-06-29 DOI: 10.21608/RESONCOL.2018.3375.1055

M. Ellithy, Lamia Elwakil, M. Schaalan, Yomna A. El Hossamy

{"title":"Impact of Exogenous Neurotropic Factor Administration on Occurrence and Severity of Paclitaxel-Induce Neuropathy in Breast Cancer Patients. An open label Pilot Study.","authors":"M. Ellithy, Lamia Elwakil, M. Schaalan, Yomna A. El Hossamy","doi":"10.21608/RESONCOL.2018.3375.1055","DOIUrl":"https://doi.org/10.21608/RESONCOL.2018.3375.1055","url":null,"abstract":"Background: Paclitaxel-induced peripheral neuropathy (PIPN) is a common toxicity with no proven agent beneficial for prevention. The potentiality of Nerve Growth Factor (NGF) as a protective agent for PIPN was suggested by several studies. Aim: This study aimed to test the impact of exogenously administered NGF on PIPN and to assess NGF levels in relation to PIPN severity. Methods: Forty patients were prospectively randomly allocated to paclitaxel alone (control group) or paclitaxel + exogenous NGF (test group). Neuropathy occurrence and severity was assessed before enrollment and after each cycle using the European Association for Treatment of Cancer Quality of Life Questionnaire for Chemotherapy Induced Peripheral Neuropathy (EORTC QLQ-CIPN20). Nerve Growth Factor level was assessed in both groups at baseline and at the end of the study. Nerve Growth Factor safety was assessed by laboratory investigations and the occurrence of adverse drug reactions. Results: There was significant increase in the EORTC QLQ-CIPN20 score in the control group (p<0.001) and a stabilization in the score in the test group. Nerve Growth Factor levels significantly increased in the test group (p<0.001) and declined in the control group. A highly significant negative correlation existed between NGF level and the EORTC QLQ-CIPN20 score (r=-0.781, p<0.001). No significant difference was observed between the two groups in the occurrence of adverse drug reactions or other toxicities. Conclusion: Exogenous NGF may have a potential neuroprotective effect against PIPN in breast cancer patients. Higher endogenous NGF level is inversely correlated with the occurrence and severity of PIPN.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42575869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Value of Serum Neopterin in Breast Cancer 血清新蝶呤在乳腺癌中的临床价值

Research in Oncology Pub Date : 2018-04-01 DOI: 10.1016/S0959-8049(18)30363-0

S. Gohar, S. Alhassanin, A. Shehata, Shaimaa Soliman

引用次数: 1